Chinese Pharma Growth Expected to Slow Amid Reform Turbulences and Intensified Cost Containment
Summary
According to data released by the National Bureau of Statistics (NBS), the revenues of the Chinese pharmaceutical manufacturing sector grew 29.37% reaching CNY 1,452.2 billion last year.Matching this observation, the Chinese pharmaceutical industry performance in 2011 can be characterized as sustained high revenue growth at lower profit margins in the backdrop of intensified government cost containment.Now in its sixth edition, this best-selling reference will continue to play an instrumental role in helping executives understand, navigate, manage and lead their pharmaceutical businesses in China.The China Pharmaceutical Guide 2012 (7th Edition) has been thoroughly updated with ample latest data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies.Its coverage was renewed and expanded significantly in the following areas:- Hundreds of pages of new data, information, analysis and case studies.- Thorough summaries and analysis of the latest healthcare reform, drug pricing & reimbursement and hospital tender purchase policies.- Comprehensive industry, market and international trade data as well as health statistics are updated with the 2011 (full year) and early 2012 figures.- A new chapter on “Social Media Strategies and Opportunities for Pharma Companies” and new data on Chinese online drug sales.- Expanded coverage high growth market segments including oncology, diabetes, cardiovascular diseases and hepatitis, and added coverage of regional markets, especially those in the Yangtze River vicinity.- Updated coverage of emerging legal issues (including FCPA/compliance issues) and drug-related IP concerns, as well as new commentaries on recommended approaches for government affairs in China’s healthcare sector.- Comprehensive top line data and research findings from their collaborative partners such as IMS Health, Kantar Health, Nicholas Hall, ZS Associates and RDPAC.- All regulatory changes in 2011/2012 are updated to present a clear and most up-to-date picture of the Chinese drug regulatory framework with summaries and analysis of all drug regulations in effect by June 30, 2012.- An updated section covering proposed new drug-related laws and regulations under the drafting process with previews of the draft versions.- Overview of China’s 12th Five-Year Plans for the pharmaceutical and related industries, as well as other long term industrial planning documents and foreign investment guidelines of the government.- Extensive review and analysis of China’s drug registration applications and approvals as well as Chinese drug innovation trends in recent years.- Comprehensive review of Sino-foreign M&A, joint venture, strategic alliance, licensing, research partnerships, co-marketing, and new drug research events in 2011 and early 2012.- New and expanded coverage on MNC strategies in China with healthcare reform in the backdrop, intellectual property/patent law amendments, data exclusivity, patent litigation, drug regulations, pharma marketing and distribution strategies, drug consumption patterns, the Chinese R&D and outsourcing sector, clinical studies/practices, healthcare reform, community healthcare sector, essential drug policy, regional drug consumption patterns, and the vaccine and API sectors.- Numerous new case studies are added to the 2012 Edition.- Comprehensive revision of the China operation profiles of MNCs to reflect their latest performance, business deals, legal disputes and outlook.All purchasers of the China Pharmaceutical Guide 2012 will receive one-year complimentary subscription of Pharma China Weekly e-Alert (Premium Edition) which provides a weekly summary of the top Chinese pharmaceutical news and Breaking News Alerts which notifies subscribers of any major unfolding events in the Chinese pharmaceutical and healthcare sectors.For further information, please contact WiCON International Group to request a free promotional PDF containing the executive summary, the table of contents, the lists of tables and charts, and preface/bio of the author.To download a brochure/order form and our promotional PDF online (available after 06/2012), please visit: http://www.pharmachinaonline.com/download/index.asp.WiCON International Group LLCTel: +1 609-9190898 Fax: +1 702-9953905e-mail: info@pharmachinaonline.com Web: www.pharmachinaonline.comWiCON International Group is the publisher of Pharma China (www.pharmachinaonline.com), the most influential English media and source of business intelligence covering the Chinese pharmaceutical / biopharmaceutical sector.Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful intelligence on China’s burgeoning but increasingly complex healthcare marketplace.